KPBMA bring international partners to Milner affiliate network
We are delighted to share that KPBMA (Korea Pharmaceutical and Bio-Pharma Manufacturers Association) has joined as an Affiliated Organization of the Milner Therapeutics Institute today. KPBMA is the largest industry member organization in South Korea, which is based...
Astellas join Milner Therapeutics Consortium
We are delighted to announce that Astellas have joined the Milner Therapeutics Consortium as our 11th pharma partner. Astellas, a global pharmaceutical company headquartered in Japan, works across more than 70 countries in the US, Europe and Asia. They bring to the...
Milner Institute announced as finalist for OBN Award
We are proud to announce that the Milner Therapeutics Institute has been shortlisted for a 2021 OBN Award in the category for Most Impactful Business Support Organisation. The OBN Awards, now in their 13th year, celebrate individuals and life sciences companies that...
Milner collaboration uncovers promising target for new drug development
Research in the Tzelepis lab, in collaboration with scientists from the Wellcome Sanger Institute and Harvard University, has identified a protein that plays a key role in transforming normal tissue to cancerous, as a possible target for drug development. The...